METFORMIN AND PROPRANOLOL COMBINATION USED FOR TREATMENT OF M-406 MAMMARY TUMOR

MARÍA VIRGINIA BAGLIONI; NAHUEL CESATTI LALUCE; ANGELA OVIEDO; VIVIANA R. ROZADOS; O. GRACIELA SCHAROVSKY; MARÍA JOSÉ RICO; MAURICIO MENACHO MÁRQUEZ

Mar del Plata

Congreso; LXI Reunión Anual de la Sociedad de Investigación Clínica; 2016

SAIC

Drug repositioning refers to the use of drugs designed for other uses that showed an antitumor effect. Metformin (M) is an antidiabetic drug, and propranolol (P) is a β-blocker. We recently found that M+P combination could be effective for triple negative breast cancer (TNBC) treatment. In this work we evaluated the effect of M and P on proliferation, apoptosis, vascularization, and modulation of the immune system (IS). Also, we evaluated the use of M+P combination as adjuvant therapy. To this aim, mice were challenged s.c. with M-406 tumor; 3 days later they were divided in 4 groups and treated in the drinking water as follows: C) no treatment; M) 2g/l M; P) 25 mg/l P; M+P) combined treatment. When tumors were exponentially growing, they were excised and used for immunohistochemistry (IHC) or disrupted and used for flow cytometry. IHC analysis indicated that there was a significant decrease in proliferation for all treated groups (Ki67 IHC; P